CD274 and melanoma: To investigate the clinical utility of a positive result for PD-L1 by RNA-seq, IHC or both, we evaluated ORR in RCC (n = 45), melanoma (n = 76), and NSCLC (n = 88) patients receiving an FDA-approved ICI (Additional file 1: Table S1).